期刊文献+

Dying T lymphocytes call for the death of tumor cells

Dying T lymphocytes call for the death of tumor cells
下载PDF
导出
摘要 Immunotherapy that specifically targets tumor cells is the preferred approach to induce tumor regression.Over the pastdecade,significant progress has been made in devising various methods to direct the immune system to respond to tumorcells.The major hurdle for successful immunotherapy is to overcome immune tolerance in the tumor microenvironment.Recent clinical trials with dendritic cell-based vaccination[1,2]and CTLA4 blocking antibodies[3]have shown greatpromise,though complete cancer regression is not always achieved[4].Currently,alternative strategies potentially leadingto cancer eradication or regression in animal or clinical models are being enthusiastically pursued.In this issue of CellResearch,Wang et al.report a novel way to induce tumor immunity by the use of irradiated autologous T cells[5]. Immunotherapy that specifically targets tumor cells is the preferred approach to induce tumor regression. Over the past decade, significant progress has been made in devising various methods to direct the immune system to respond to tumor cells. The major hurdle for successful immunotherapy is to overcome immune tolerance in the tumor microenvironment. Recent clinical trials with dendritic cell-based vaccination [1, 2] and CTLA4 blocking antibodies [3] have shown great promise, though complete cancer regression is not always achieved [4]. Currently, alternative strategies potentially leading to cancer eradication or regression in animal or clinical models are being enthusiastically pursued. In this issue of Cell Research, Wang et al. report a novel way to induce tumor immunity by the use of irradiated autologous T cells [5].
出处 《Cell Research》 SCIE CAS CSCD 2006年第8期679-680,共2页 细胞研究(英文版)
  • 相关文献

参考文献1

二级参考文献45

  • 1Hajnzic TF, Kastelan M, Lukac J, Hajnzic T. Immunocompetent cells and lymphocyte reactivity to mitogens in levamisole-treated brain tumor children. Pediatr Hematol Oncol 1999;16:335- 340.
  • 2Tang J, Flomenberg P, Harshyne L, et al. Glioblastoma patients exhibit circulating tumor-specific CD8+ T cells. Clin Cancer Res 2005;11:5292-5299.
  • 3Aarnoudse CA, van den Doel PB, Heemskerk B, Schrier PI. Interleukin-2-induced, melanoma-specific T cells recognize CAMEL, an unexpected translation product of LAGE-1. Int J Cancer 1999; 82:442-451.
  • 4Liu SH, Zhang M, Zhang WG. Strategies of antigen-specific T-cell-based immunotherapy for cancer. Cancer Biother Radiopharm 2005; 20:491-501.
  • 5Hong J, Zang Y, Tejada-Simon M, et al. Reactivity and regula- tory properties of human anti-idiotypic antibodies induced by T cell vaccination in patients with multiple sclerosis. J Immunol 2000; 165:6858-6864.
  • 6Shapira OM, Mot E, ReshefT, et al. Prolongation of survival of rat cardiac allografts by T cell vaccination. J Clin Invest 1993; 91:388-390.
  • 7Rakhmilevich AL, Timmins JG, Janssen K, et al. Gene gunmediated IL-12 gene therapy induces antitumor effects in the absence of toxicity: a direct comparison with systemic IL-12 protein therapy. J Immunother 1999; 22:135-144.
  • 8Kanwar JR, Shen WE Kanwar RK, Berg RW, Krissansen GW. Effects of survivin antagonists on growth of established tumors and B7-1 immunogene therapy. J Natl Cancer Inst 2001; 93:1541 - 1552.
  • 9Kumar V, Sercarz E, Zhang JW, Cohen I. T cell vaccination: from basics to the clinic. Trends Immunol 2001; 22:539-544.
  • 10Kozovska ME, Hong J, Zang YCQ, et al. Interferon beta induces T-helper 2 immune deviation in MS. Neurology 1999; 53:1692- 1697.

共引文献4

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部